DUBLIN and ATLANTA, April 7, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced new data from the largest head-to-head comparative trial of transfemoral transcatheter aortic valve replacement (TAVR), were presented as a late breaking clinical trial at the American College of Cardiology Annual Scientific Session and simultaneously published in The New England Journal of Medicine. The one-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial in individuals with aortic stenosis (AS) with small aortic annuli (SAA) demonstrated noninferior clinical outcomes and superior valve performance as measured by bioprosthetic valve dysfunction performance for the Evolut™ TAVR platform compared to the SAPIEN™ platform.
Medtronic opens its expanded innovation centre in Hyderabad
Medtronic lifts annual profit forecast, exits ventilator business
Dec 13 (Reuters) - Medtronic (MDT.N) said on Wednesday that the U.S. Food and Drug Administration (FDA) had approved its system for a type of condition that can cause stroke or heart failure.
DUBLIN, Dec. 7, 2023 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, December 7, 2023, approved the company's cash dividend for the third quarter of fiscal year 2024 of $0.69 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2023. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 46 consecutive years. The dividend is payable on January 12, 2024, to shareholders of record at the close of business on December 20, 2023.
Nov 21 (Reuters) - Medtronic (MDT.N) raised its annual earnings forecast on Tuesday as strong sales in its surgical and diabetes units allayed concerns about the impact of new diabetes and weight-loss drugs on long-term growth, sending its shares up nearly 4% in morning trade.
Nov 17 (Reuters) - The U.S. Food and Drug Administration on Friday approved the use of Medtronic's (MDT.N) treatment device in a surgery called renal denervation in patients whose high blood pressure cannot be controlled by drugs, the company said.
FDA medical device recalls typically involve hardware that poses a risk to patients, either because they are operating or being operated incorrectly—but, on some rare occasions, they involve products that were never meant to be used in the first place.
Aug 23 (Reuters) - The U.S. Food and Drug Administration's (FDA) independent experts on Wednesday narrowly voted against recommending the approval of Medtronic's (MDT.N) blood pressure treatment device, saying risks tied to using it do not outweigh the benefits.
After cutting costs earlier this year—including through a rolling wave of worldwide layoffs—Medtronic is starting off its 2024 fiscal year with reports of single-digit sales growth across each of its business areas.